| Value | ₹7.06 Cr |
|---|
NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,049.00
- Market cap
- ₹50,312 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.6×Sector 46.1×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Other Announcement
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma Annual General Meeting
Gland Pharma issued a postal ballot notice to seek shareholder approval for appointing Mr. Xingli Wang as Non-Executive Director. E-voting runs October 7 to November 5, 2026.
Gland Pharma Management Change
Gland Pharma Limited announced the resignation of director Wenjie Zhang and the appointment of Xingli Wang as a Non-Executive Non-Independent Director effective October 1, 2026.
Gland Pharma Acquisition Worth ₹199.5 Cr
Gland Pharma Limited's board approved a USD 21 million investment in its subsidiary, Gland USA, to acquire a 60% stake in Novelstar Pharma Inc. This acquisition facilitates business expansion in the USA.
- Value
- ₹199.5 Cr
- Execution
- By October 31, 2026
Other legal & regulatory announcements
All →Coromandel International Legal & Regulatory
Coromandel International received a Deputy Commissioner (Appeal) GST order-in-appeal for FY 2019-20 confirming ineligible input tax credit demand. The company will appeal before GSTAT and expects no significant financial impact.
- Value
- ₹0.18 Cr
Taurian Mps Legal & Regulatory
Taurian MPS received a SEBI adjudication order imposing penalties of Rs.5 lakh on the company, Rs.5 lakh on promoters jointly, and Rs.8 lakh on the merchant banker. The penalties relate to IPO offer document disclosure deficiencies.
- Value
- ₹0.05 Cr
Coromandel International Legal & Regulatory
Coromandel International received a GST Order-in-Appeal confirming a ₹1.79 Crore tax demand. Including interest and penalty, the total is ₹4.05 Crore; the company will appeal.
- Value
- ₹4.05 Cr
Shreeji Global FMCG Legal & Regulatory
Shreeji Global FMCG received a customs Order-in-Original demanding about ₹42.47 Crore in duty, penalties and redemption fines. The company plans to appeal before CESTAT.
- Value
- ₹42.47 Cr
HD Fire Protect Legal & Regulatory
HD Fire Protect received an MPCB refusal of Consent to Operate for its Jalgaon expansion sheds. Existing manufacturing operations continue, with no material impact anticipated.
Krishna Institute of Medical Sciences Legal & Regulatory
KIMS discloses a pending suit over its Chennai hospital land lease, naming it defendant. Supreme Court dismissed its SLP; no injunction halts the project.